Sophia Genetics, a Switzerland-based clinical insights platform, has raised $110m in its series F round from a consortium including Hitachi Ventures, the investment arm of conglomerate Hitachi.
Venture capital firm aMoon led the round, which took total funding to $250m. Other investors included Swisscom Ventures, the corporate venturing unit of the local telecoms operator, banks Credit Suisse and Pictet and investment firms Endeavour Vision, Generation Investment Management, Alychlo, Eurazeo Growth, ACE & Company and Famille C Invest.
This followed a series E round led by Generation Investment Management in January 2019. The company completed a $30m series D round in 2017 that was led by VCs Balderton and included 360º Capital Partners, Invoke Capital and Alychlo.
Swisscom had participated in a $13.8m series B round for Sophia in 2014 that was led by Invoke and backed by Endeavour Vision, before Marc Coucke led the company’s $15m series C round the following year.
Founded in 2011, Sophia has developed a clinical genomics analytics platform intended to help healthcare professionals diagnose and treat patients for cancer and hereditary disorders by more thoroughly analysing genomic and radiomic data. It also provides a network that enables users to share genomic data.
Keiji Kojima, executive vice president and general manager of Hitachi’s Smart Life business division, said: “Over the years, Sophia Genetics has emerged as a leader in data-driven medicine and we look forward to supporting the company expand its footprint in the Japanese market and beyond.”
